Nxera Pharma Co., Ltd. (SOLTF)
SOLTF Stock Price Chart
Explore Nxera Pharma Co., Ltd. interactive price chart. Choose custom timeframes to analyze SOLTF price movements and trends.
SOLTF Company Profile
Discover essential business fundamentals and corporate details for Nxera Pharma Co., Ltd. (SOLTF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Sept 2013
Employees
387.00
Website
https://soseiheptares.comCEO
Christopher Cargill
Description
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
SOLTF Financial Timeline
Browse a chronological timeline of Nxera Pharma Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Apr 2026
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 31 Oct 2025
Revenue estimate is $7.00B.
Earnings released on 8 Aug 2025
EPS came in at -$0.18 falling short of the estimated -$0.03 by -515.47%, while revenue for the quarter reached $58.63M , missing expectations by -99.43%.
Earnings released on 2 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.27 by +78.94%, while revenue for the quarter reached $44.29M , beating expectations by +2.74%.
Earnings released on 11 Feb 2025
EPS came in at -$0.09 falling short of the estimated $0.05 by -279.06%, while revenue for the quarter reached $43.58M , missing expectations by -36.84%.
Earnings released on 1 Nov 2024
EPS came in at $0.09 surpassing the estimated $0.00 by +4.67K%, while revenue for the quarter reached $64.44M , missing expectations by -26.25%.
Earnings released on 9 Aug 2024
EPS came in at -$0.10 falling short of the estimated $0.00 by -19.85K%, while revenue for the quarter reached $50.49M , missing expectations by -4.74%.
Earnings released on 9 May 2024
EPS came in at -$0.24 falling short of the estimated $0.12 by -294.06%, while revenue for the quarter reached $30.40M , missing expectations by -54.64%.
Earnings released on 27 Mar 2024
EPS came in at -$0.02 falling short of the estimated $0.03 by -163.05%, while revenue for the quarter reached $52.13M , beating expectations by +17.28%.
Earnings released on 30 Sept 2023
EPS came in at -$0.40 falling short of the estimated $0.21 by -295.06%, while revenue for the quarter reached $22.27M , missing expectations by -52.46%.
Earnings released on 30 Jun 2023
EPS came in at -$0.06 , while revenue for the quarter reached $8.32M , missing expectations by -44.01%.
Earnings released on 31 Mar 2023
EPS came in at -$0.13 , while revenue for the quarter reached $7.12M , beating expectations by +0.27%.
Earnings released on 14 Feb 2023
EPS came in at $44.03 , while revenue for the quarter reached $53.41M , beating expectations by +29.76%.
Earnings released on 11 Nov 2022
EPS came in at $3.82 , while revenue for the quarter reached $42.77M , missing expectations by -16.46%.
Earnings released on 10 Aug 2022
EPS came in at -$17.95 , while revenue for the quarter reached $9.84M , beating expectations by +9.57%.
Earnings released on 13 May 2022
EPS came in at -$25.39 , while revenue for the quarter reached $9.15M , beating expectations by +2.25%.
Earnings released on 10 Feb 2022
EPS came in at $28.21 , while revenue for the quarter reached $122.78M , beating expectations by +11.83%.
Earnings released on 11 Nov 2021
EPS came in at $5.80 , while revenue for the quarter reached $4.19M .
Earnings released on 12 Aug 2021
EPS came in at -$14.11 , while revenue for the quarter reached $17.24M .
Earnings released on 12 May 2021
EPS came in at -$14.28 , while revenue for the quarter reached $10.92M .
Earnings released on 12 Feb 2021
EPS came in at $39.80 , while revenue for the quarter reached $42.57M .
Earnings released on 11 Nov 2020
EPS came in at $5.94 , while revenue for the quarter reached $18.26M .
SOLTF Stock Performance
Access detailed SOLTF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.